CompletedPhase 2NCT00195624

Alemtuzumab to Treat Severe Aplastic Anemia

Studying Aplastic Anemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator
Neal S Young, M.D.
National Heart, Lung, and Blood Institute (NHLBI)
Intervention
Alemtuzumab (Campath )(biological)
Enrollment
47 enrolled
Eligibility
2-110 years · All sexes
Timeline
20052018

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00195624 on ClinicalTrials.gov

Other trials for Aplastic Anemia

Additional recruiting or active studies for the same condition.

See all trials for Aplastic Anemia

← Back to all trials